Login
Elicio Therapeutics, Inc. logo

Elicio Therapeutics, Inc.

elicio.com

What Do They Do?

Develops ready-made cancer immunotherapies targeting tumor mutations for patients with pancreatic, colorectal and other cancers.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▲ +21% (Loss)
vs −$10.1M in Q3 FY2025

From fibrosis drugs to cancer immunotherapies The older report describes a small-molecule drug pipeline for fibrotic and other diseases; the latest report centers on ready-made immunotherapies targeting tumor mutations in cancers.

Who Do They Compete With?

Competes with Amgen, Mirati Therapeutics, AstraZeneca, BioNTech, BridgeBio Oncology Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Circio, D3 Bio, Eli Lilly, Erasca, Geneos, Gilead Sciences, Incyte, Jacobio Pharma, Jiangsu Hengrui Pharmaceuticals, Merck, Moderna, Roche, and Revolution Medicines

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support